Transaction Report:
(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) Editor: Nonia Pariente 1st Editorial Decision 01 October 2013
Thank you for your patience while your study has been under peer-review at EMBO reports. As you will see from the reports pasted below, the are disparate opinions among the referees. Referee 2 is rather negative about the advance provided, whereas referees 1 and 3 consider that a strengthened manuscript would be suitable for publication here.
As the reports are pasted below, I will not detail them here. Overall, I think the study is a good candidate for consideration in EMBO reports after appropriate revision. Please note that the following issues would have to be addressed during revision for the study to be successful here:
-all the technical concerns brought up by referee 1 need to be addressed, and the data tightened up with the new controls, image analysis and text rewriting -additional evidence of the role of TBC1D5, following the suggestions of referee 3, would also be necessary (which would also alleviate some of referee 2's concerns)
As you may remember, it is EMBO reports policy to undergo one round of revision only and thus, acceptance of your study will depend on the outcome of the next, final round of peer-review, which will involve referees 1 and 3.
Given the recent publication of a study showing AP2-dependent trafficking of ATG9 from the plasma membrane, it would be ideal if your revision could be submitted in the shortest time frame possible, and always within our standard three months of revision.
Revised manuscript length must be a maximum of 28,500 characters (including spaces). When submitting your revised manuscript, please also include editable TIFF or EPS-formatted figure files, a separate PDF file of any Supplementary information (in its final format) and a letter detailing your responses to the referees.
We also welcome the submission of cover suggestions or motifs that might be used by our Graphics Illustrator in designing a cover.
I look forward to seeing a revised form of your manuscript when it is ready. In the meantime, do not hesitate to get in touch with me if I can be of any assistance.
REFEREE REPORTS:
Referee #1 (Report):
Popovic and Dikic here continue their investigation into the role of TBC1D5 in endocytic trafficking and autophagy. As they have shown TBC1D5 is interacts with retromer as well as LC3 they explore the relationship between TBC1D5-directed sorting with other endocytic processes, and look at the function of TBC1D5 in the context of sorting Atg9 in this process, and in particular between the plasma membrane and the retromer-positive endosomal compartment. In addition, they examine the role of AP2 in this process and interactions. Their conclusions are the Atg9 trafficking is regulated under starved conditions by a dynamic interaction with TBC1D5 and AP2. While a few of the data are convincing enough to support their interesting hypothesis, the manuscript is far below the standard expected for EMBO Reports. Much of the data is not presented or explained well enough to be convincing and the manuscript is poorly written and the text at times confusing and contradictory. Some points are listed below, (please note this is not an extensive list), to provide some guidance for improvement of all the data presented.
Major points: 1. Many of the immunoprecipitations are done with M2 beads and the control is untransfected or uninduced lysates. The additional control of transfected lysates with a non-relevant antibody and beads without antibody is needed. When agarose is used ( Fig. 3F and S7B there is no input shown and the condition is not specificed). 2. The use false coloring, the contrast and presentation of the immunofluorscence, and the choice of fluorophores (cy5 and mCherry) for instance make the images very unconvincing. See for example Fig. 1G right, S1B where the 2 or 3 channels are impossible to identify in the merge, and the contrast seems to be enhanced in the merge. 3. The Atg9, LC3 and AP2 stainings vary widely and appear different in several images. Compare for instance for Atg9 2B and 3D, for AP2 3D and E, 5A. LC3 in many images appears vey diffuse even under conditions where one would expect discrete spots (see 1C, S3 lower, 6B Fig. S7 appears to contradict much of the other data, and doesn't show extended starvation periods, they have used standard conditions. 8. Fig. 1I and 5C are unlabelled. 9. Other comments: DFCP-1 is not an Atg protein; autophagyc should be autophagic.
Referee #2 (Report):
This paper reports the following observations: 1. TBC1D5 associates with ATG9 and ULK1 2. TBC1D5 is required for ATG9 trafficking -in the absence of TBC1D5, cells have decreased numbers of ATG9 vesicles and these are mislocalised to late endosomes when autophagy is induced. 3. TBC1D5 and ATG9 interact with the AP2 complex -the authors suggest that since TBC1D5 depletion reduced the ATG9-AP2 interaction, TBC1D5 is acting as an adaptor 4. AP2 and clathrin-mediated endocytosis is required for ATG9 sorting and autophagy.
The timing of this paper is unfortunate as Rubinsztein's group have recently shown that ATG9 is in clathrin-coated pits and is endocytosed in an AP2-and dynamin-dependent manner (Cell 2013 (Cell 154: 1285 (Cell -1299 . So the novelty of the last part of the paper, which may be the most interesting component, is lost. Furthermore, Dikic's group have previously described that TBC1D5 is involved in autophagosome formation.
In order for the current paper to have impact now, we need to understand what TBC1D5 is doing. It is not clear if it is really acting as an adaptor -if ATG9 vesicle numbers are decreased and ATG9 is mislocalised after TBC1D5 knockdown, then this may explain why there is less ATG-AP2 interaction in the knockdown cells -maybe the ATG9 is mislocalised and less is at the plasma membrane. This may be additionally explained as the knockdown cells have less AP2, so this in itself could explain the data in 3G -the AP2 may not bind less effectively molecule-by-molecule but there may be simply less of it to bind the ATG9. Much more work will be required to show that TBC1D5 is an adaptor for ATG and AP2. The data presented also do not explain how the TBC1D5 knockdown causes the mislocalisation of the ATG9 in late endosomes.
Thus, I do not think that the current study has sufficient novelty and depth for EMBO Reports.
Referee #3 (Report):
In this manuscript, the authors reported that TBC1D5 and AP2 regulate Atg9 trafficking. The authors found that TBC1D5 can interact with Ap2 and Atg9, and depletion of TBC1D5 leads to missorting Atg9 into late endosome.
The membrane source of autophagosome is one of fundamental questions in autophagy field. Plasma membrane has been identified as one potential source for autophagosome membrane. Very recently, Atg9 has been reported to trafficking from plasma membrane to early endosome through clathrin-coated structure. Thus identifying TBC1D5 and Ap2 as new components regulating Atg9 trafficking is a timely and important discovery.
I have a few suggestions on this manuscript.
1) Could the authors elaborate more on why Atg9 colocalizes with TGN in Ap2 depleted cells upon autophagy induction? One will expect that Atg9 stays at plasma membrane under this condition.
2) Could the authors explain why TBC1D5 depletion causes Atg9 missorting into late endosome? Does it imply that TBC1D5 regulates sorting of Atg9 from early endosome to autophagosome, rather than plasma membrane to early endosome? In this scenario, TBC1D5 depletion will cause the defection of sorting of Atg9 from early endosome to autophagsosome, thus cause the missorting Atg9 to late endosome.
3) The authors proposed TBC1D5 as the adaptor linking Atg9 to AP2. The authors should test whether knockdown TBC1D5 can reduce the colocalization between Ap2 /clathrin and Atg9. 4) Does TBC1D5 affect endocytosis in general?
Minor points: 1) LC3 puncta formation in TBC1D5 depleted cells should be shown.
2) The conclusion drawn from Dynasore need backing by the data from a dominant negative mutant of Dynamin 2. Page5: "large patches"--We intended to refer to the domains on plasma membrane that were enriched in AP2, TBC1D5 and ATG9 proteins. As suggested, we changed the text and use "plasma membrane regions enriched with AP2/ATG9/TBC1D5" instead of "large patches".
Fig. S7 appears to contradict much of the other data, and doesn't show extended starvation periods, they have used standard conditions.
In order to emphasize the general message of the manuscript, we provide a new blot showing that dynamin2 inhibitor Dynasore enhances interaction of TBC1D5 and ATG9, which can be additionally increased by starvation or abolished upon knock--down of AP2 (Fig. 5F ). Therefore we excluded previous Fig. S7 . 8. Fig. 1I and 5C are unlabelled. We provided new figure 1I and we labeled both, Fig. 1I and Fig. 5C We appreciate reviewer's comments and suggestions. It was indeed unfortunate that upon submission of our manuscript, the paper from the Rubinzstein lab appeared in Cell. We have not been aware of their findings prior to the publication and we have now referenced their work. The Puri et al. manuscript shows that ATG9 localizes on the plasma membrane in clathrin--coated structures and is internalized following a classical endocytic pathway through early and then recycling endosomes. They have also shown that these vesicles fuse with the ATG16--positive pool at the site of autophagosomal formation. We feel that our studies are complementary to this report as we identify the molecular machinery that underlies the basis of ATG9 trafficking from the plasma membrane toward the autophagosome formation. In particularly, we demonstrate that TBC1D5 links AP2 endocytic complex with the ATG9 trafficking route. We provide evidence that clathrin mediated endocytosis is essential for trafficking of ATG9 and extend these findings by showing that this process is also dependent on the AP2 complex as well as on the RabGAP protein TBC1D5. We also show that upon depletion of TBC1D5, co--localization of ATG9 and AP2 is decreased (Fig. S6B) , which additionally supports our hypothesis that TBC1D5 regulates autophagy via direct binding to LC3 and subsequent recruitment of AP2--clathrin vesicles that contain ATG9, and that effect is specific for TBC1D5 depletion and not only caused by decrease in total AP2. We did not intend to make a general statement that TBC1D5 is an AP2 adaptor, despite the fact that it binds to AP2. We rather propose that via direct binding to both, LC3 and AP2, TBC1D5 is able to regulate ATG9 trafficking to the site of phagophore formation, as depletion of AP2 abolishes their interaction and affects autophagy flux, similarly to depletion of TBC1D5. Thank you very much for the final reviews of our manuscript. We are pleased with the positive comments by the Reviewers and the Editorial Board. We have incorporated all of the suggested corrections, including the changes in the title and abstract. Also there is a minor change in the proposed model:
-Proposed model in the Fig. 5 .: we added additional arrow pointing to the secretion from TGN to endosomes (since this is critical route of the CI-M6PR and potentialy ATG9 secretion, and has been neglected in previous picture).
We hope that the current manuscript contains all necessary corrections and is suitable for the publication in EMBO Reports.
Looking forward to hearing from you. I am very happy to accept your manuscript for publication in the next available issue of EMBO reports.
As part of the EMBO publication's Transparent Editorial Process, EMBO reports publishes online a Review Process File to accompany accepted manuscripts. As you are aware, this File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
If you do NOT want this File to be published, please inform the editorial office within 2 days, if you have not done so already, otherwise the File will be published by default [contact: emboreports@embo.org]. If you do opt out, the Review Process File link will point to the following statement: "No Review Process File is available with this article, as the authors have chosen not to make the review process public in this case."
Thanks again for your contribution to EMBO reports and congratulations on a successful publication. Please consider us again in the future for your most exciting work.
